TY - JOUR
T1 - Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population
AU - Ciruelos, E.
AU - Jerusalem, G.
AU - Martin, M.
AU - Tjan-Heijnen, V. C.G.
AU - Neven, P.
AU - Gavila, J.
AU - Montemurro, F.
AU - Generali, D.
AU - Lang, I.
AU - Martínez-Serrano, M. J.
AU - Perelló, M. F.
AU - Conte, P.
N1 - Funding Information:
E. Ciruelos declare her participation in advisory boards of Roche, Lilly, Pfizer and Novartis and received speakers’ honoraria from Roche, Lilly, Pfizer and Novartis as well as non-financial support from Roche. G. Jerusalem declare research grants from Novartis, Roche and Pfizer, personal fees from Novartis, Roche, Pfizer, Lilly, Celgene, Amgen, BMS and AstraZeneca, and non-financial support from Novartis, Roche, Lilly, Pfizer, Amgen, BMS and AstraZeneca. M. Martin declare research grants from Roche and Novartis, speaker’s honoraria from Roche, AstraZeneca, GSK, Pfizer and Lilly and participated in advisory boards of Roche, AstraZeneca, GSK, Lilly, Pfizer Taiho and Pharmamar. V. C. G. Tjan-Heijnen declare research grants and non-financial support from Novartis, Pfizer, Roche, Lilly and AstraZeneca. J. Gavila declare speakers’ honoraria and participation in advisory boards from Pfizer, Roche and Novartis. F. Montemurro declare speakers’ honoraria from Novartis, Lilly and Pfizer and participated in advisory boards of Roche. D. Generali declare speakers’ honoraria from Novartis, Lilly and Pfizer. M. J. Martínez-Serrano and M. F. Perelló are Novartis’ employees. P. Neven and I. Lang and P. Conte declare that they have no conflict of interest.
Publisher Copyright:
© 2020, Federación de Sociedades Españolas de Oncología (FESEO).
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Background: The addition of everolimus to exemestane therapy significantly improves progression-free survival in postmenopausal patients with hormone-receptor (HR)-positive HER2-negative endocrine-resistant breast cancer. However, the safety profile of this schedule still might be optimized. Methods: Patients included in the BALLET trial were assessed. The objectives of this analysis were to provide additional information on the safety profile of this schedule depending on prior anticancer therapies and to characterize the time course of adverse events (AEs) and serious AEs (SAEs) of clinical interest throughout the study period. Non-infectious pneumonitis (NIP), stomatitis, asthenia and weight loss were selected as AEs of clinical interest. Results: The safety population of this analysis comprised 2131 patients. There were similar incidences of AEs and SAEs of clinical interest regardless of previous anticancer therapies. Most stomatitis and asthenia events occurred within the first three months. Incidence of weight loss appeared to plateau except in the case of grade 3–4 events, which occurred rarely. The incidence of any grade NIP (between 2 to 6%) and grade 3–4 NIP (between 0 to 1%) was low across the study, but steady. Conclusions: Everolimus plus exemestane is a well-known therapeutic option for aromatase inhibitor pretreated advanced breast cancer patients, and its toxicity profile is similar to that described in previous studies. Close monitoring, especially within the first three months, early intervention with preventive measures and patient education to help recognize the first signs and symptoms of AEs, will help to reduce their incidence and severity.
AB - Background: The addition of everolimus to exemestane therapy significantly improves progression-free survival in postmenopausal patients with hormone-receptor (HR)-positive HER2-negative endocrine-resistant breast cancer. However, the safety profile of this schedule still might be optimized. Methods: Patients included in the BALLET trial were assessed. The objectives of this analysis were to provide additional information on the safety profile of this schedule depending on prior anticancer therapies and to characterize the time course of adverse events (AEs) and serious AEs (SAEs) of clinical interest throughout the study period. Non-infectious pneumonitis (NIP), stomatitis, asthenia and weight loss were selected as AEs of clinical interest. Results: The safety population of this analysis comprised 2131 patients. There were similar incidences of AEs and SAEs of clinical interest regardless of previous anticancer therapies. Most stomatitis and asthenia events occurred within the first three months. Incidence of weight loss appeared to plateau except in the case of grade 3–4 events, which occurred rarely. The incidence of any grade NIP (between 2 to 6%) and grade 3–4 NIP (between 0 to 1%) was low across the study, but steady. Conclusions: Everolimus plus exemestane is a well-known therapeutic option for aromatase inhibitor pretreated advanced breast cancer patients, and its toxicity profile is similar to that described in previous studies. Close monitoring, especially within the first three months, early intervention with preventive measures and patient education to help recognize the first signs and symptoms of AEs, will help to reduce their incidence and severity.
KW - Aromatase inhibitors
KW - Breast neoplasm
KW - Endocrine therapy
KW - Everolimus
KW - Post-menopausal women
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85082701028&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082701028&partnerID=8YFLogxK
U2 - 10.1007/s12094-020-02327-5
DO - 10.1007/s12094-020-02327-5
M3 - Article
C2 - 32170637
AN - SCOPUS:85082701028
VL - 22
SP - 1857
EP - 1866
JO - Clinical and Translational Oncology
JF - Clinical and Translational Oncology
SN - 1699-048X
IS - 10
ER -